Atorvastatin Calcium
Pronouncation: (ah-TOR-va-STAT-in KAL-see-um)Class: HMG-CoA reductase inhibitor
Trade Names:
Lipitor
- Tablets 10 mg
- Tablets 20 mg
- Tablets 40 mg
- Tablets 80 mg
Pharmacology
 | ||||||||||||
Feedback for Atorvastatin Calcium
| ||||||||||||
Increases rate at which body removes cholesterol from blood and reduces production of cholesterol by inhibiting enzyme that catalyzes early rate-limiting step in cholesterol synthesis; increases HDL; reduces LDL, VLDL, and triglycerides (TGs).
Pharmacokinetics
Absorption
Rapidly absorbed; T max is 1 to 2ߙh. Bioavailability is approximately 14%; low bioavailability is because of presystemic Cl in GI mucosa and/or hepatic first-pass metabolism. Food decreases rate and extent of absorption approximately 25% and 9%, respectively, but does not alter efficacy.
Distribution
Vd is approximately 381 L. At least 98% is protein bound.
Metabolism
Undergoes hepatic and extrahepatic metabolism, including first-pass metabolism and CYP3A4. Extensively metabolized to active metabolites, which produce approximately 70% of circulating inhibitory activity of HMG-CoA reductase.
Elimination
Atorvastatin and metabolites eliminated primarily in bile. Less than 2% of dose is recovered in the urine. Plasma t ½ is approximately 14 h.
Duration
The t ½ of HMG-CoA reductase inhibition is 20 to 30 h.
Special Populations
Hepatic Function ImpairmentPlasma levels are markedly increased in patients with chronic alcoholic liver disease.
Indications and Usage
CVReduce risk of MI or stroke and reduce risk for revascularization procedures and angina in patients with multiple risk factors for coronary heart disease (CHD), such as age, smoking, hypertension, low HDL cholesterol (C), or family history of early CHD. Reduce risk of non-fatal MI and fatal and non-fatal stroke in patients with type 2 diabetes, and without clinically evident CHD, but with multiple risk factors for CHD, such as albuminuria, hypertension, retinopathy, or smoking. Reduce risk of angina, non-fatal MI, and fatal and non-fatal stroke, or hospitalization for CHD, and reduce risk for revascularization procedures in patients with clinically evident CHD.
HypercholesterolemiaAdjunct to diet to reduce elevated total-C, LDL-C, apolipoprotein B (apo B), and TG levels, and increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb). Adjunct to diet for treatment of patients with elevated serum TG levels (Fredrickson type IV). Treatment of primary dysbetalipoprotein (Fredrickson type III) in patients who do not respond adequately to diet. Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (LDL aphaeresis), or if such treatments are unavailable. Adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls 10 to 17 yr of age with heterozygous familial hypercholesterolemia if, after an adequate trial of diet therapy, the following are present: LDL-C remains at a level of at least 190 mg/dL; LDC-C remains at a level of least 160 mg/dL and there is a positive family history of premature CV disease; 2 or more other CV disease risk factors are present in children.
Contraindications
Active liver disease or unexplained persistent elevation of serum transaminases; pregnancy; lactation; hypersensitivity to any component of the product.
Dosage and Administration
AdultsPO 10 to 80 mg/day.
Heterozygous Familial HypercholesterolemiaChildren 10 to 17 yr of age
PO Start with 10 mg/day (max, 20 mg/day).
Storage/Stability
Store tablets at controlled room temperature (68° to 77°F).
Drug Interactions
Antacids, colestipol, rifampinCoadministration may decrease atorvastatin levels.
Azole antifungal agents (eg, itraconazole), cyclosporine, diltiazem, gemfibrozil, grapefruit juice, macrolide antibiotics (eg, erythromycin), niacin, NNRTIs, protease inhibitors (eg, ritonavir), verapamilSevere myopathy or rhabdomyolysis may occur.
Contraceptives, oralMay increase AUC for norethindrone and ethinyl estradiol.
DigoxinElevated digoxin levels may occur.
Laboratory Test Interactions
None well documented.
Adverse Reactions
CNS
Headache (17%); asthenia (4%); dizziness, insomnia (at least 2%).
Dermatologic
Rash (4%); bullous rashes including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (postmarketing).
EENT
Sinusitis (6%); pharyngitis (3%); rhinitis (at least 2%).
GI
Diarrhea (5%); abdominal pain (4%); constipation, dyspepsia, flatulence (3%); nausea (at least 2%).
Genitourinary
Albuminuria, hematuria, UTI (at least 2%).
Metabolic
Peripheral edema (at least 2%).
Musculoskeletal
Myalgia (6%); arthralgia (5%); back pain (4%); arthritis (at least 2%); rhabdomyolysis (postmarketing).
Respiratory
Bronchitis (at least 2%).
Miscellaneous
Accidental injury (4%); flu-like symptoms (3%); chest pain (at least 2%); anaphylaxis, angioneurotic edema (postmarketing).
Precautions
MonitorCPK levelsIf muscle tenderness, pain, and/or weakness develop during therapy, determine CPK levels. If CPK levels are markedly increased or if muscle symptoms continue or worsen, be prepared to discontinue therapy. Serum C/TGsEnsure serum C and TGs are measured before therapy is started, within 2 to 4 wk after starting therapy or changing the atorvastatin dose, and then periodically thereafter. Serum transaminase levelsIf elevated serum transaminase levels develop during treatment, or if signs or symptoms of liver disease (eg, abdominal pain, dark urine, fatigue, flu-like symptoms, persistent nausea, right-upper quadrant, yellowing of skin or eyes) are noted, repeat transaminase levels more frequently. If transaminase levels rise to 3 times ULN or greater and persist, be prepared to discontinue therapy. |
Pregnancy
Category X .
Lactation
Contraindicated in breast-feeding women.
Children
Safety and efficacy not established, except in children 10 to 17 yr of age with heterozygous familial hypercholesterolemia.
Hypercholesterolemia
Ensure secondary causes of hypercholesterolemia (eg, poorly controlled diabetes, hypothyroidism, drugs that increase LDL-C and decrease HDL-C) are excluded, or, if appropriate, treated, before starting therapy.
LFTs
Ensure that LFTs (transaminases) are determined before and 12 wk following initiation of therapy, after increase in dose, and periodically thereafter (eg, every 6 mo).
Liver disease
Use with caution in patients who consume substantial quantities of alcohol or have a history of liver disease.
Myopathy
Ensure therapy is temporarily withheld in patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, hypotension, major surgery, sepsis, trauma).
Skeletal muscle effects
Rhabdomyolysis with renal function impairment secondary to myoglobinuria has occurred in this class of drugs. Consider myopathy in any patient with diffuse myalgias, muscle tenderness or weakness, or marked elevation of CPK.
Patient Information
- Explain name, dose, action, potential side effects of medication, and cholesterol goals.
- Advise patient that dose of medication may change, based on results of cholesterol blood tests, in an effort to reach cholesterol goals.
- Advise patient to take prescribed dose once daily without regard to meals, but to take with food if stomach upset occurs.
- Advise patient to try to take each dose at about the same time each day.
- Caution patient not to take atorvastatin with grapefruit juice.
- Advise patient that if a dose is missed to take as soon as remembered but to never take more than 1 dose of atorvastatin a day.
- Advise patient that atorvastatin helps control, but does not cure, cholesterol abnormality and to continue taking as prescribed when cholesterol goals has been reached.
- Emphasize to patient the importance of other modalities for cholesterol control: dietary changes (eg, reduced saturated fat intake, increased soluble fiber intake), weight control, regular exercise, and smoking cessation.
- Instruct patient to continue taking other cholesterol-lowering medications as prescribed by health care provider.
- Instruct patient to immediately notify health care provider if experiencing dark urine; fatigue; flu-like symptoms; pain under the right rib cage; persistent nausea; unexplained muscle pain, tenderness, and/or weakness; yellowing of skin or eyes; or any other unusual feelings.
- Advise women of childbearing potential to use effective contraception during treatment with atorvastatin.
 |
Link to Page |  |
Print Page |  |
Email Page |  | Add to List |
High Cholesterol - Familial Homozygous, High Cholesterol, High Cholesterol - Familial Heterozygous, Prevention of Cardiovascular Disease, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL)
